Lundbeck hopes long-term Covid-19 effects will boost Trintellix
In a new study by Canadian researchers, Lundbeck's antidepressant dug Trintellix will be tested as a treatment for the long-term cognitive effects of Covid-19.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY DANIEL PEDERSEN
Canadian scientist Roger McIntyre will spearhead a new clinical trial, including 200 participants, to investigate whether Lundbeck's drug Trintellix, which is normally used in depression treatment, can potentially treat Covid-19 long-term effects, reports Danish business daily Børsen.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Lundbeck starts new study of tablet version of drug
For subscribers
